163 related articles for article (PubMed ID: 36791561)
21. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma.
Zhang J; Liu Y; Liu Z; Wang XM; Yin DT; Zheng LL; Zhang DY; Lu XB
Int J Med Sci; 2013; 10(5):585-92. PubMed ID: 23533107
[TBL] [Abstract][Full Text] [Related]
22. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
[TBL] [Abstract][Full Text] [Related]
23. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
[TBL] [Abstract][Full Text] [Related]
24. The role of miRNAs in the pathogenesis and therapeutic resistance of endometrial cancer: a spotlight on the convergence of signaling pathways.
Abdelmaksoud NM; El-Mahdy HA; Ismail A; Elsakka EGE; El-Husseiny AA; Khidr EG; Ali EM; Rashed MH; El-Demerdash FE; Doghish AS
Pathol Res Pract; 2023 Apr; 244():154411. PubMed ID: 36921547
[TBL] [Abstract][Full Text] [Related]
25. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
Wu YC; Li SY; Jia YF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
[TBL] [Abstract][Full Text] [Related]
27. Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer.
Soleimani A; Rahmani F; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
Curr Pharm Des; 2018; 24(39):4605-4610. PubMed ID: 30636581
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma.
Liu F; Yin R; Chen X; Chen W; Qian Y; Zhao Y; Jiang Y; Ma D; Hu T; Yu T; Zhu Y; Zhang Y
Biomed Pharmacother; 2019 Jun; 114():108605. PubMed ID: 30904818
[TBL] [Abstract][Full Text] [Related]
29. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.
Minna E; Romeo P; De Cecco L; Dugo M; Cassinelli G; Pilotti S; Degl'Innocenti D; Lanzi C; Casalini P; Pierotti MA; Greco A; Borrello MG
Oncotarget; 2014 May; 5(9):2513-28. PubMed ID: 24810336
[TBL] [Abstract][Full Text] [Related]
30. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway.
Xu J; Cai J; Jin X; Yang J; Shen Q; Ding X; Liang Y
Oncol Rep; 2015 Sep; 34(3):1424-30. PubMed ID: 26133772
[TBL] [Abstract][Full Text] [Related]
31. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
32. miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells.
Luo L; Xia L; Zha B; Zuo C; Deng D; Chen M; Hu L; He Y; Dai F; Wu J; Wang C; Wang Y; Zhang Q
Biomed Pharmacother; 2018 Oct; 106():983-990. PubMed ID: 30119270
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic regulation of papillary thyroid carcinoma by long non-coding RNAs.
Lin RX; Yang SL; Jia Y; Wu JC; Xu Z; Zhang H
Semin Cancer Biol; 2022 Aug; 83():253-260. PubMed ID: 33785446
[TBL] [Abstract][Full Text] [Related]
35. miRNAs as cornerstones in colorectal cancer pathogenesis and resistance to therapy: A spotlight on signaling pathways interplay - A review.
Elrebehy MA; Al-Saeed S; Gamal S; El-Sayed A; Ahmed AA; Waheed O; Ismail A; El-Mahdy HA; Sallam AM; Doghish AS
Int J Biol Macromol; 2022 Aug; 214():583-600. PubMed ID: 35768045
[TBL] [Abstract][Full Text] [Related]
36. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
[TBL] [Abstract][Full Text] [Related]
37. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling.
Zhang X; Li M; Zuo K; Li D; Ye M; Ding L; Cai H; Fu D; Fan Y; Lv Z
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1305-13. PubMed ID: 23796566
[TBL] [Abstract][Full Text] [Related]
38. [Advances in studies of the genes related to thyroid carcinoma].
Zhi JT; Zheng XQ; Gao M
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Dec; 51(12):951-955. PubMed ID: 27978891
[TBL] [Abstract][Full Text] [Related]
39. Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review.
Chruścik A; Lam AK
Exp Mol Pathol; 2015 Dec; 99(3):393-8. PubMed ID: 26321247
[TBL] [Abstract][Full Text] [Related]
40. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
Wang Y; Hou P; Yu H; Wang W; Ji M; Zhao S; Yan S; Sun X; Liu D; Shi B; Zhu G; Condouris S; Xing M
J Clin Endocrinol Metab; 2007 Jun; 92(6):2387-90. PubMed ID: 17426084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]